Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
about
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsThe role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerTreatment of advanced squamous cell carcinoma of the lung: a reviewDacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancerProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerThe Evolution of Therapies in Non-Small Cell Lung CancerThe Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled TrialsIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughShould Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized TrialsOptimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptorEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesγδ T cells for cancer immunotherapy: A systematic review of clinical trialsUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewTailored therapy in lung cancerProposing Essential Medicines to Treat Cancer: Methodologies, Processes, and OutcomesNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateEpidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published dataChemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial dataA multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Molecular pathways and therapeutic targets in lung cancerNew developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerExtraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report.A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerSequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidencePeripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancerPhase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System.miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type.Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
P2860
Q26744339-65D68CAB-F189-4EB0-898E-FDB4D411A698Q26749110-CD0EF793-E6F0-4E84-A362-3C34D04F489EQ26775392-5B32A46D-E162-4EDF-AD68-DC7684C1FF5CQ26778318-C19F741B-D1FF-46AE-B805-CDA457F40DE2Q26781810-94168354-8975-49BD-83DA-554B5FD8EAFCQ26784298-F98E766C-A1AA-49D3-A793-20BB49363727Q26786932-9ADEA219-E875-4829-8095-6F66F73FB034Q26796549-9DB32F80-A16F-4BB4-B594-2D28C6FC0C23Q26798882-C6DFF570-9241-4AD5-A269-1292778AD923Q26799467-12153EC2-CEF0-4D79-A9A8-6780049B993CQ26825636-26655B1C-2244-480D-AF31-7400C7066218Q26859993-7A00421F-E8A8-436A-AAA2-87DA3AF49635Q26995204-AABCB76A-8CFE-4B6B-A6C8-ECF7060BEDDFQ27003440-A1C5AD13-EA3E-4524-8549-6AEAAB4C55A3Q27014117-962FD92B-E813-423C-9D84-31421C46D096Q27021705-9B7019AE-AC21-45A9-9B82-5E5488B61780Q27022535-56429445-08E6-4FEA-877F-BEA1FF015995Q27026316-1F33E9CC-0D8C-4FED-BD9E-800D9B1B81B2Q28081319-C2F411C0-9912-4545-92AA-29F3393674BCQ29620913-76509240-1969-4A8F-92F1-BA359B198A21Q30356434-CF1AEC0C-7EC5-43BE-A197-E46D4B4751F2Q30850656-35AEDA78-9967-405C-834D-C9CB222B541CQ30871237-A8F0C6F2-42F0-4B68-852E-3C05D46B23F3Q30940337-3A5EDA05-B6D5-4C36-B3BE-05333C13DF1BQ33435236-87E734B3-279A-4D07-8E24-D13868779E45Q33598423-8E4724F8-2FB6-4176-9EB1-C20EC5F60727Q33688872-B24E703D-327F-4706-AE2A-82DAC2A1E709Q33704088-99BAEC96-C415-4064-8A1F-96BA832FEF66Q33710152-9BA14AAD-37DD-4A73-B7A6-8970A9EFAA3EQ33739969-A34E415B-E78F-47B8-A621-AC43072B078BQ33857726-24DCF4EA-227A-4AE1-9D9B-11FD879A3E7EQ33873095-2A1F541E-A924-4063-8070-7C0DBBD747AEQ33995172-D99215B9-3440-4737-81BD-2A7CC7294490Q34011705-8ACB80F3-E5DD-49B8-A53A-EAE5DC6F39F7Q34092157-43DB6577-40EB-408F-A793-AC4220EEDAC9Q34143354-A98E6315-ED8E-45C3-BE1F-51771A5E86AAQ34265813-3C606FE4-6F3D-4654-8867-EF4B5971CC85Q34365935-28C37EC5-EECB-46CD-BA60-276B99B61A5EQ34430535-E3A74F96-D73F-4BEA-9FC8-1B5E01E25F19Q34452186-B67F005A-EB44-4190-A791-149E76DB422E
P2860
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Erlotinib versus docetaxel as ...... a randomised controlled trial.
@en
Erlotinib versus docetaxel as ...... cer and wild-type EGFR tumours
@nl
type
label
Erlotinib versus docetaxel as ...... a randomised controlled trial.
@en
Erlotinib versus docetaxel as ...... cer and wild-type EGFR tumours
@nl
prefLabel
Erlotinib versus docetaxel as ...... a randomised controlled trial.
@en
Erlotinib versus docetaxel as ...... cer and wild-type EGFR tumours
@nl
P2093
P50
P1433
P1476
Erlotinib versus docetaxel as ...... a randomised controlled trial.
@en
P2093
Alberto Scanni
Anna Bettini
Calogero Lauricella
Eliana Rulli
Filippo Bianchi
Flavia Longo
Gabriella Farina
Irene Floriani
Luca Moscetti
Marina Chiara Garassino
P304
P356
10.1016/S1470-2045(13)70310-3
P577
2013-07-22T00:00:00Z